Evidence map›Paper›PMID 38058839›Full record

ArticleAmerican journal of cancer research2023

Prognostic impact of cortactin in patients with hypopharyngeal cancer and its role for tegafur-uracil maintenance after adjuvant chemoradiotherapy.

Ching-Feng Lien, Tzer-Zen Hwang, Tsun-Mei Lin, Kai-Wen Liu, Bor-Shyh Lin, Chih-Chun Wang, Chuan-Chien Yang, Shyh-An Yeh, Meng-Che Hsieh

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ching-Feng LienDepartment of Otolaryngology, E-Da Hospital Kaohsiung, Taiwan.
Tzer-Zen HwangDepartment of Otolaryngology, E-Da Hospital Kaohsiung, Taiwan.
Tsun-Mei LinCollege of Medicine, I-Shou University Kaohsiung, Taiwan.
Kai-Wen LiuCollege of Medicine, I-Shou University Kaohsiung, Taiwan.
Bor-Shyh LinInstitute of Imaging and Biomedical Photonics, National Chiao Tung University Tainan, Taiwan.
Chih-Chun WangDepartment of Otolaryngology, E-Da Hospital Kaohsiung, Taiwan.
Chuan-Chien YangDepartment of Otolaryngology, E-Da Hospital Kaohsiung, Taiwan.
Shyh-An YehCollege of Medicine, I-Shou University Kaohsiung, Taiwan.
Meng-Che HsiehCollege of Medicine, I-Shou University Kaohsiung, Taiwan.
National Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients with hypopharyngeal cancer (HPC) remains poor. Our study aims to investigate the prognostic impact of cortactin in patients with HPC and its role for tegafur-uracil (UFUR) maintenance after adjuvant chemoradiotherapy (CRT). Patients who were diagnosed to have HPC and underwent laryngopharyngectomy followed by adjuvant CRT were enrolled into our study. Immunohistochemical staining was performed for cortactin evaluation. Kaplan-Meier curves were depicted for recurrence-free survival (RFS) and overall survival (OS). A total of 157 patients were enrolled into our study. After stratified by cortactin, 53 patients were cortactin (+) and 104 patients were cortactin (-). The median RFS was 86.7 months in cortactin (-) and 10.2 months in cortactin (+) (P < 0.001). The median OS was 93.4 months in cortactin (-) and 16.9 months in cortactin (+) (P < 0.001). Patients were further classified according to UFUR maintenance or not after adjuvant CRT. In cortactin (+) patients, the median RFS and OS were 13.6 months versus 7.0 months (P = 0.006) and 24.0 months versus 10.0 months (P < 0.001) in UFUR (+) and UFUR (-), respectively. In cortactin (-) patients, the median RFS and OS were 96.0 months versus 72.2 months (P = 0.262) and 98.5 months versus 105.0 months (P = 0.665) in UFUR (+) and UFUR (-), respectively. Cortactin has a significantly impact in HPC patients. UFUR maintenance provided survival benefits in patients with cortactin (+) after adjuvant CRT.

Indexed as

chemoradiotherapyCortactinhypopharyngeal cancerprognosissurvivaltegafur-uracil

Identifiers

PMID38058839
PMCPMC10695800
OpenAlexW4389452997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.